Company Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-01 EDT			5-day change	1st Jan Change
0.649 ^USD	+3.02%		-2.20%	-55.55%

04-25	Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	CI
01-12	Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023	CI

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Number of employees: 11

USD in Million	2022	Weight	2023	Weight	Delta
ViraxClear and ViraxImmune 100.0 %	0	nan %	0	100.0 %	-

USD in Million	2022	Weight	2023	Weight	Delta
United Kingdom, Hong Kong, Singapore, China, British Virgin Islands 100.0 %	0	nan %	0	100.0 %	-

Managers	Title	Age	Since
James Foster CEO	Chief Executive Officer	37	12-12-31
Jason Davis DFI	Director of Finance/CFO	52	22-05-01
Mark Ternouth CTO	Chief Tech/Sci/R&D Officer	56	-
Tomasz George CTO	Chief Tech/Sci/R&D Officer	40	21-01-31
Nigel McCracken COO	Chief Operating Officer	-	23-08-31

Members of the board	Title	Age	Since
Nelson Haight BRD	Director/Board Member	58	-
Evan Norton BRD	Director/Board Member	49	-
James Foster CEO	Chief Executive Officer	37	12-12-31
Mark Ternouth CTO	Chief Tech/Sci/R&D Officer	56	-
Yair Erez BRD	Director/Board Member	50	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,361,903	1,729,013 ( 73.20 %)	0	73.20 %

Name	Equities	%	Valuation
James Foster 12.19 %	287,987	12.19 %	206 487 $
Cameron Shaw 8.810 %	208,094	8.810 %	149 203 $
Armistice Capital LLC 5.165 %	121,999	5.165 %	87 473 $
Patrick Henry Cunliffe Foster 4.462 %	105,388	4.462 %	75 563 $
Tomasz George 1.078 %	25,466	1.078 %	18 259 $
Virtu Financial LLC 0.4507 %	10,644	0.4507 %	7 632 $
Mark Ternouth 0.2521 %	5,955	0.2521 %	4 270 $
UBS Securities LLC 0.0282 %	665	0.0282 %	477 $
Wells Fargo Clearing Services LLC 0.008468 %	200	0.008468 %	143 $

Virax Biolabs Group Ltd.

20 North Audley Street

W1K 6LX, London

http://www.viraxbiolabs.com

address Virax Biolabs Group Limited(VRAX)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIRAX BIOLABS GROUP LIMITED	-55.55%	1.49M
IQVIA HOLDINGS INC.	+0.67%	42.19B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.2B
MEDPACE HOLDINGS, INC.	+29.96%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.76B
UNITED THERAPEUTICS CORPORATION	+16.03%	10.4B
BIO-TECHNE CORPORATION	-4.80%	9.94B

Other Biotechnology & Medical Research